KLRSHealthcare · Biotechnology

KLRS Stock Forecast: Kalaris Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$3.20

+1.27% on the day

The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. hold a median 12-month price target of $20 — +525.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$76.2M

Ticker Nerd rank

20 / 100

Median analyst target

$20

Analysts covering

Revenue$0.0

Operating income−$12.4M

Net income−$11.5M

Free cash flow−$11.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−5.3%

−20.6%

YTD

−62.1%

−27.1%

From 52W high

−70.9%

From 52W low

+1.3%

$11

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

KLRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kalaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Quality

Momentum

Growth

Volatility

Accruals

Issuance

Value

Size (79): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KLRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KLRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts

7 Buy1 Hold0 Sell

Low $7Median $20High $25

The green dot is the last close — the median target sits +525.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
15 June 2026	TD Cowen	Initiates	Buy	—
14 May 2026	Wedbush	Initiates	Outperform	—
13 May 2026	Citizens	Maintains	Market Outperform	—
16 Apr 2026	Morgan Stanley	Initiates	Overweight	—
23 Dec 2025	Chardan Capital	Initiates	Buy	—
3 Nov 2025	Citizens	Initiates	Market Outperform	—
3 Sept 2025	Raymond James	Initiates	Strong Buy	—
8 Apr 2025	William Blair	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KLRS appears on the weeks it earns a place.

Performance

KLRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Kalaris Therapeutics, Inc. returned −27.1% against +16.3% for the S&P 500, dividends included.

KLRS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KLRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Kalaris Therapeutics, Inc. (KLRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.1×
Price / sales: —
Price / book: 1.3×
EV / EBITDA: 0.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −79.9%
Return on assets: −31.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kalaris Therapeutics, Inc. (KLRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Kalaris Therapeutics, Inc. has a market value of $76.2M and an enterprise value of −$16.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$44.3M.
Free cash flow in the twelve months to 30 June 2026: −$41.2M.
Shares outstanding: 23.8M.
Trailing P/E: −1.1×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Kalaris Therapeutics, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

KLRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
KLRSKalaris Therapeutics, Inc.	$76.2M	20
XBITXBiotech, Inc.	$66.8M	31
APLMApollomics, Inc.	$68.3M	18
RNTXRein Therapeutics, Inc.	$68.4M	37
GOSSGossamer Bio, Inc.	$65.6M	47
PLRXPliant Therapeutics, Inc.	$68.7M	67
ELOXEloxx Pharmaceuticals, Inc.	$70.4M	12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kalaris Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KLRS news & analysis

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 31 Aug 2026neutral

Kalaris Therapeutics announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company is developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.

Why it matters — A KLRS watcher would care because management's appearance at a major healthcare conference provides a platform to discuss the company's clinical-stage pipeline, including its lead candidate TH103.

FAQ

Frequently asked questions about KLRS stock

What is the KLRS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KLRS stock a buy right now?

Of the 8 analysts covering Kalaris Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kalaris Therapeutics, Inc. 20 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KLRS?

As at 19 Sept 2026, Kalaris Therapeutics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will KLRS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +525.0% from the last close, and Ticker Nerd's factor model ranks Kalaris Therapeutics, Inc. 20 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KLRS stock forecast for 2030?

No analyst covering Kalaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.

How has KLRS stock performed over the past year?

Kalaris Therapeutics, Inc. returned -27.1% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kalaris Therapeutics, Inc. do?

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs.

What is the latest news on KLRS?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference". Kalaris Therapeutics announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company is developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.

Company

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs. The company’s lead program is TH103, an investigational anti-VEGF therapy designed for exudative and neovascular retinal conditions, including neovascular age-related macular degeneration. Kalaris Therapeutics also works on extending TH103’s use across other retinal disorders such as diabetic macular edema and retinal vein occlusion. Its current business centers on ophthalmology and biotechnology, where it aims to address sight-threatening diseases through targeted retinal therapies. The company is headquartered in the United States and operates as a specialist developer within the broader healthcare market.

CEO Mr. Andrew Oxtoby · 20 employees · United States · https://kalaristx.com